Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.
about
Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancerIxabepilone for the treatment of solid tumors: a review of clinical dataNovel non-AR therapeutic targets in castrate resistant prostate cancerIxabepilone: a new antimitotic for the treatment of metastatic breast cancer.Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortPhase II trial of weekly ixabepilone in men with metastatic castrate-resistant prostate cancer (E3803): a trial of the Eastern Cooperative Oncology GroupA phase II trial of the epothilone B analog ixabepilone (BMS-247550) in patients with metastatic melanoma.Update on options for treatment of metastatic castration-resistant prostate cancerBeyond taxanes: a review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins.Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trialsCOOPERATIVE GROUP TRIALS - SOUTHWEST ONCOLOGY GROUP (SWOG) INNOVATIONS IN ADVANCED PROSTATE CANCER.Therapies in development for castrate-resistant prostate cancer.Novel microtubule-targeting agents - the epothilones.Ixabepilone (ixempra), a therapeutic option for locally advanced or metastatic breast cancer.Castration-resistant prostate cancer: new science and therapeutic prospects.Synergistic activity of ixabepilone plus other anticancer agents: preclinical and clinical evidence.The epothilones: new therapeutic agents for castration-resistant prostate cancer.Castration-resistant prostate cancer: mechanisms, targets, and treatment.Chemotherapy in Androgen-Independent Prostate Cancer (AIPC): What's next after taxane progression?Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials ConsortiumEvolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancerA phase II trial of ixabepilone in Asian patients with advanced gastric cancer previously treated with fluoropyrimidine-based chemotherapy.Bladder carcinoma: understanding advanced and metastatic disease with potential molecular therapeutic targets.Epothilones in the treatment of cancer.Management of prostate cancer. Part 3: metastatic disease.Systemic chemotherapy options for metastatic bladder cancer.New molecular targets in advanced prostate cancer.Novel agents and targets in managing patients with metastatic prostate cancer.Development of new cancer therapeutic agents targeting mitosis.Novel therapies in genitourinary cancer: an update.Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors.Novel therapeutic strategies in development for prostate cancer.Current management of prostate cancer: dilemmas and trialsPhase I trial and pharmacokinetic study of ixabepilone administered daily for 5 days in children and adolescents with refractory solid tumorsProstate cancer chemotherapy in the era of targeted therapy.Assessing outcomes in prostate cancer clinical trials: a twenty-first century tower of Babel.Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancerThe optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer.The epothilones: how pharmacology relates to clinical utility.Emerging drugs for prostate cancer.
P2860
Q27010542-BF229108-942C-433A-9B4B-09DB67A1F3C7Q28271570-DB27A458-567F-4DAB-93CE-7DDA73EB55DFQ28383663-0F0460FB-5978-4B91-AF9F-9B700959E5B5Q33380465-2DF90C32-6A1B-4164-8193-31C642000760Q33384027-455E4B3E-0611-41AB-B9FB-C8574EA8946CQ33400047-9868040F-9947-41CA-858C-EB5B8EA74C52Q33526311-043930CC-D2D2-4D84-86BE-1E2A8E59D55AQ33956051-652EB4BC-48E4-42A7-899B-7C2CD1EDECC2Q33999018-2D59DBE6-9B3C-48DF-9387-29E44D23DE87Q34180965-74435293-DA21-42DE-9118-CD292C876145Q34309132-41A783D4-2A66-422B-AEFF-5FF8248153F8Q34588402-470F80FC-CAD6-4AAA-8378-23F30DC84254Q34611212-C5FC23A3-13B3-458A-98C7-7B977C973531Q34611801-F99B0CD4-A1B1-425D-8F5C-ECFAA92E03C0Q35076264-684D48A3-B071-4089-81C8-E1E97B027635Q35076330-93FB49FA-3EE9-4E00-AED6-CD7C4FF6619FQ35584399-1F3434DF-BD75-46FB-B0AA-6192DD318B31Q35864027-3E8587CF-7033-4D95-B741-7DF1705D6C29Q35945262-B6044579-CAD8-4E03-9994-CA3BA03A86F1Q36184242-7236501C-5703-4DB2-A096-BFDDA73A1871Q36241242-3E11B53B-880C-4349-8441-CF70E24DA338Q36275405-1C646B56-3064-475E-B0CD-3BF6B1EB2664Q36334889-7B7FD05F-EFFD-4748-973F-CE056B30D1D2Q36491842-7CA2F0A7-0D4A-4DC8-B50A-3198F1DAB292Q36499259-BDDF2646-B737-43C7-A3DC-A91925D6CF08Q36500537-3833C200-0959-4E59-A01A-4D7152FA65D3Q36532080-EC6BB5E8-E194-483D-8A48-E22FAEA61056Q36555662-D1BB049B-CD89-49A7-B2B5-6E09C9C88D41Q36623076-3277BBCF-1022-49E8-AAC4-9B43C3911FF7Q36856612-B6515032-5ADF-409C-9AB9-FCE178CEA706Q36988082-A04F2C36-64B0-4707-B27B-8FA71B3AB74EQ37038977-81F3AC15-A871-4BD1-8365-F9C1D5D13309Q37102535-3AAB5A9D-09BA-4D4F-9712-7D5841C7EB7DQ37104791-440ADB60-0B7D-4C70-83A1-930F0CB7BEC6Q37180864-98261A0E-F302-4142-B9B8-83828E3B384AQ37255452-89ABE0DB-EEC5-43F8-9866-AE73AB25CC31Q37290709-A558F3BB-71CD-4AF0-8F17-94DCF09EF4B2Q37378233-06809785-8EEE-4E06-A839-D11E101AAE68Q37543912-5FC4C14F-08DB-4278-A59A-52E2EC2E9C0AQ37570555-324BB161-895F-4775-9068-2346271933A1
P2860
Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.
description
2005 nî lūn-bûn
@nan
2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Ixabepilone (epothilone B anal ...... st Oncology Group trial S0111.
@ast
Ixabepilone (epothilone B anal ...... st Oncology Group trial S0111.
@en
type
label
Ixabepilone (epothilone B anal ...... st Oncology Group trial S0111.
@ast
Ixabepilone (epothilone B anal ...... st Oncology Group trial S0111.
@en
prefLabel
Ixabepilone (epothilone B anal ...... st Oncology Group trial S0111.
@ast
Ixabepilone (epothilone B anal ...... st Oncology Group trial S0111.
@en
P2093
P356
P1476
Ixabepilone (epothilone B anal ...... st Oncology Group trial S0111.
@en
P2093
A Dimitrios Colevas
Catherine M Tangen
Daniel P Petrylak
E David Crawford
Maha Hussain
Primo N Lara
Ulka N Vaishampayan
Wael A Sakr
P304
P356
10.1200/JCO.2005.02.4448
P407
P50
P577
2005-12-01T00:00:00Z